Vor Biopharma Inc. (VOR)

Vor Biopharma Inc. (VOR) is a healthcare company (biotechnology) based in the United States. The share price is $18.30, down 3.53% on the day, which values the company at $1.12B. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$18.30−3.53% today
Market value
$1.12B
P/E ratio
0.1×last 12 months
200-week average
$34.6247% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Vor Biopharma Inc. in more detail

VOR trades at 0.1× its last twelve months' earnings, -5.5× next year's expected earnings. It sits 47% below its 200-week average of $34.62.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold VOR, including Peter Kolchinsky (0.4% of the portfolio).

Superinvestors holding VOR

1 of the investors tracked here report a position in their latest 13F filing.

Vor Biopharma Inc. (VOR): questions and answers

What is VOR's P/E ratio?

Vor Biopharma Inc. trades at 0.1× its last twelve months' earnings and -5.5× next year's expected earnings.

What is Vor Biopharma Inc.'s market cap?

Vor Biopharma Inc. is valued at $1.12B at a share price of $18.30.

Is VOR above its 200-week moving average?

No. VOR is 47.1% below its 200-week average of $34.62. Long-term investors watch that line because strong companies rarely trade below it for long.

Does VOR pay a dividend?

Vor Biopharma Inc. does not currently pay a regular dividend.

Which famous investors own VOR?

In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio) hold VOR. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Vor Biopharma Inc. (VOR) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/VOR

Underlying data: Yahoo Finance; company filings with the SEC.